-
1
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
-
(2003)
N Engl J Med
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
Gathmann, I.4
Baccarani, M.5
Cervantes, F.6
-
2
-
-
0142026838
-
Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans
-
Baars A, Pinedo HM. Goede respons op de selectieve tyrosinekinaseremmer imatinib bij een patiënt met gemetastaseerd dermatofibrosarcoma protuberans. Ned Tijdschr Geneeskd 2003;147:2072-6.
-
(2003)
Ned Tijdschr Geneeskd
, vol.147
, pp. 2072-2076
-
-
Baars, A.1
Pinedo, H.M.2
-
3
-
-
0142122115
-
Enkele patiënten met een gemetastaseerde gastro-intestinale stromaceltumor: Gekeerde kansen door de introductie van imatinib
-
Gelderblom H, Verweij J. Enkele patiënten met een gemetastaseerde gastro-intestinale stromaceltumor: gekeerde kansen door de introductie van imatinib. Ned Tijdschr Geneeskd 2003;147:2041-3.
-
(2003)
Ned Tijdschr Geneeskd
, vol.147
, pp. 2041-2043
-
-
Gelderblom, H.1
Verweij, J.2
-
4
-
-
0142058816
-
Imatinib, een specifieke tyrosinekinaseremmer, voor de behandeling van patiënten met een gastro-intestinale stromaceltumor
-
Gelderblom H, Hogendoorn PCW, Graaf WTA van der, Verweij J. Imatinib, een specifieke tyrosinekinaseremmer, voor de behandeling van patiënten met een gastro-intestinale stromaceltumor. Ned Tijdschr Geneeskd 2003;147:2051-5.
-
(2003)
Ned Tijdschr Geneeskd
, vol.147
, pp. 2051-2055
-
-
Gelderblom, H.1
Hogendoorn, P.C.W.2
Van der Graaf, W.T.A.3
Verweij, J.4
-
5
-
-
0037186924
-
Imatinib mesylate - A new oral targeted therapy
-
Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-93.
-
(2002)
N Engl J Med
, vol.346
, pp. 683-693
-
-
Savage, D.G.1
Antman, K.H.2
-
6
-
-
0037343949
-
Polycythemia vera responds to imatinib mesylate
-
Jones CM, Dickinson TM. Polycythemia vera responds to imatinib mesylate. Am J Med Sci 2003;325:149-52.
-
(2003)
Am J Med Sci
, vol.325
, pp. 149-152
-
-
Jones, C.M.1
Dickinson, T.M.2
-
7
-
-
0038717050
-
Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera
-
Silver RT. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. Leukemia 2003:17:1186-7.
-
(2003)
Leukemia
, vol.17
, pp. 1186-1187
-
-
Silver, R.T.1
-
8
-
-
0037018763
-
Treatment of hypereosinophilic syndrome with imatinib mesilate
-
Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002;359:1577-8.
-
(2002)
Lancet
, vol.359
, pp. 1577-1578
-
-
Gleich, G.J.1
Leiferman, K.M.2
Pardanani, A.3
Tefferi, A.4
Butterfield, J.H.5
-
9
-
-
85117738579
-
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy
-
ter perse
-
Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood [ter perse].
-
Blood
-
-
Pardanani, A.1
Ketterling, R.P.2
Brockman, S.R.3
Flynn, H.C.4
Paternoster, S.F.5
-
10
-
-
0038386031
-
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
-
Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 2003;101:3391-7.
-
(2003)
Blood
, vol.101
, pp. 3391-3397
-
-
Pardanani, A.1
Reeder, T.2
Porrata, L.F.3
Li, C.Y.4
Tazelaar, H.D.5
Baxter, E.J.6
-
11
-
-
0037087531
-
Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies
-
Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1692-1703
-
-
Heinrich, M.C.1
Blanke, C.D.2
Druker, B.J.3
Corless, C.L.4
-
13
-
-
0038176390
-
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment
-
Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res 2003;9:2092-7.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2092-2097
-
-
Zonder, J.A.1
Pemberton, P.2
Brandt, H.3
Mohamed, A.N.4
Schiffer, C.A.5
-
14
-
-
0036847703
-
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571
-
McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002:8:3584-91.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3584-3591
-
-
McGary, E.C.1
Weber, K.2
Mills, L.3
Doucet, M.4
Lewis, V.5
Lev, D.C.6
-
15
-
-
0037146220
-
Potential use of imatinib in Ewing's sarcoma: Evidence for in vitro and in vivo activity
-
Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002;94:1673-9.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1673-1679
-
-
Merchant, M.S.1
Woo, C.W.2
Mackall, C.L.3
Thiele, C.J.4
-
16
-
-
0037986203
-
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells
-
Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003;88:1889-96.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 1889-1896
-
-
Podtcheko, A.1
Ohtsuru, A.2
Tsuda, S.3
Namba, H.4
Saenko, V.5
Nakashima, M.6
-
17
-
-
0034691761
-
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571
-
Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI571. Oncogene 2000;19:3521-8.
-
(2000)
Oncogene
, vol.19
, pp. 3521-3528
-
-
Wang, W.L.1
Healy, M.E.2
Sattler, M.3
Verma, S.4
Lin, J.5
Maulik, G.6
-
18
-
-
0037146228
-
Taking aim at Ewing's sarcoma: Is KIT a target and will imatinib work?
-
Druker BJ. Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? J Natl Cancer Inst 2002:94:1660-1.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1660-1661
-
-
Druker, B.J.1
-
19
-
-
0036790060
-
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy
-
Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
-
(2002)
Cancer Res
, vol.62
, pp. 5476-5484
-
-
Pietras, K.1
Rubin, K.2
Sjoblom, T.3
Buchdunger, E.4
Sjoquist, M.5
|